Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents

Radiographics

Volumn 31, Issue 6, 2011, Pages 1547-1568

  Goodwin, Mark D ^a   Dobson, Julie E ^a   Sirlin, Claude B ^b   Lim, Beng Ghee ^c   Stella, Damien L ^c  

^a AUSTIN HEALTH   (Australia)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT; DRUG DERIVATIVE; GADOBENIC ACID; GADOLINIUM ETHOXYBENZYL DTPA; GADOLINIUM PENTETATE; MEGLUMINE; ORGANOMETALLIC COMPOUND;

DIFFERENTIAL DIAGNOSIS; HUMAN; LIVER CELL; LIVER DISEASE; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW;

CONTRAST MEDIA; DIAGNOSIS, DIFFERENTIAL; GADOLINIUM DTPA; HEPATOCYTES; HUMANS; LIVER DISEASES; MAGNETIC RESONANCE IMAGING; MEGLUMINE; ORGANOMETALLIC COMPOUNDS;

EID: 84857383811     PISSN: 02715333     EISSN: 15271323     Source Type: Journal    
DOI: 10.1148/rg.316115528     Document Type: Article

References (26)

1. Filippone A, Blakeborough A, Breuer J, et al. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine. J Magn Reson Imaging 2010;31(2):356-364.
2. Ringe KI, Husarik DB, Sirlin CB, Merkle EM. Gadoxetate disodium-enhanced MRI of the liver. I. Protocol optimization and lesion appearance in the noncirrhotic liver. AJR Am J Roentgenol 2010;195 (1):13-28.
3. van Montfoort JE, Stieger B, Meijer DK, Weinmann HJ, Meier PJ, Fattinger KE. Hepatic uptake of the magnetic resonance imaging contrast agent gadoxetate by the organic anion transporting polypeptide OATP1. J Pharmacol Exp Ther 1999;290 (1):153-157.
4. Lorusso V, Pascolo L, Fernetti C, Visigalli M, Anelli P, Tiribelli C. In vitro and in vivo hepatic transport of the magnetic resonance imaging contrast agent B22956/1: role of MRP proteins. Biochem Biophys Res Commun 2002;293(1):100-105.
5. Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging-correlation with molecular transporters and histopathologic features. Radiology 2010; 256(3):817-826.
6. Kim YK, Kwak HS, Kim CS, Han YM. Detection and characterization of focal hepatic tumors: a comparison of T2-weighted MR images before and after the administration of gadoxectic acid. J Magn Reson Imaging 2009;30(2):437-443.
7. Choi JS, Kim MJ, Choi JY, Park MS, Lim JS, Kim KW. Diffusion-weighted MR imaging of liver on 3.0-Tesla system: effect of intravenous administration of gadoxetic acid disodium. Eur Radiol 2010;20 (5):1052-1060.
8. Kim KA, Kim MJ, Park MS, et al. Optimal T2- weighted MR cholangiopancreatographic images can be obtained after administration of gadoxetic acid. Radiology 2010;256(2):475-484.
9. Ringe KI, Gupta RT, Brady CM, et al. Respiratory-triggered three-dimensional T2-weighted MR cholangiography after injection of gadoxetate disodium: is it still reliable? Radiology 2010;255(2):451-458.
10. Vogl TJ, Kümmel S, Hammerstingl R, et al. Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA. Radiology 1996;200(1): 59-67.
11. Doo KW, Lee CH, Choi JW, Lee J, Kim KA, Park CM. "Pseudo washout" sign in high-flow hepatic hemangioma on gadoxetic acid contrast-enhanced MRI mimicking hypervascular tumor. AJR Am J Roentgenol 2009;193(6):W490-W496.
12. Grazioli L, Morana G, Kirchin MA, Schneider G. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine- enhanced MR imaging: prospective study. Radiology 2005;236(1):166-177.
13. Karam AR, Shankar S, Surapaneni P, Kim YH, Hussain S. Focal nodular hyperplasia: central scar enhancement pattern using gadoxetate disodium. J Magn Reson Imaging 2010;32(2):341-344.
14. Vander Borght S, Libbrecht L, Blokzijl H, et al. Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver. J Pathol 2005;207(4): 471-482.
15. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3): 1020-1022.
16. Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 2009; 44(7):793-798.
17. Lee SA, Lee CH, Jung WY, et al. Paradoxical high signal intensity of hepatocellular carcinoma in the hepatobiliary phase of Gd-EOB-DTPA enhanced MRI: initial experience. Magn Reson Imaging 2011; 29(1):83-90.
18. Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, Bolondi L. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis. Eur Radiol 2011;21(6): 1233-1242.
19. Park G, Kim YK, Kim CS, Yu HC, Hwang SB. Diagnostic efficacy of gadoxetic acid-enhanced MRI in the detection of hepatocellular carcinomas: comparison with gadopentetate dimeglumine. Br J Radiol 2010;83(996):1010-1016.
20. Kim YK, Kim CS, Han YM, Park G. Detection of small hepatocellular carcinoma: can gadoxetic acid-enhanced magnetic resonance imaging replace combining gadopentetate dimeglumine-enhanced and superparamagnetic iron oxide-enhanced magnetic resonance imaging? Invest Radiol 2010;45(11): 740-746.
21. Ahn SS, Kim MJ, Lim JS, Hong HS, Chung YE, Choi JY. Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma. Radiology 2010;255(2): 459-466.
22. Choi JY, Choi JS, Kim MJ, et al. Detection of hepatic hypovascular metastases: 3D gradient echo MRI using a hepatobiliary contrast agent. J Magn Reson Imaging 2010;31(3):571-578.
23. Kim YK, Lee JM, Kim CS, Chung GH, Kim CY, Kim IH. Detection of liver metastases: gadobenate dimeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MR imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2005;15(2):220-228.
24. Kim YK, Lee YH, Kwak HS, Kim CS, Han YM. Detection of liver metastases: gadoxetic acid-enhanced three-dimensional MR imaging versus ferucarbotran-enhanced MR imaging. Eur J Radiol 2010;73(1):131-136.
25. Morana G, Grazioli L, Kirchin MA, et al. Solid hypervascular liver lesions: accurate identification of true benign lesions on enhanced dynamic and hepatobiliary phase magnetic resonance imaging after gadobenate dimeglumine administration. Invest Radiol 2011;46(4):225-239.
26. Park Y, Kim SH, Kim SH, et al. Gadoxetic acid (Gd-EOB-DTPA)-enhanced MRI versus gadobenate dimeglumine (Gd-BOPTA)-enhanced MRI for preoperatively detecting hepatocellular carcinoma: an initial experience. Korean J Radiol 2010;11(4): 433-440.